Snap Inc (NYSE:SNAP) has announced a new multi-year agreement with Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) to power future generations of its augmented reality (AR) eyewear with Snapdragon processors. The deal centers on Snap’s subsidiary, Specs, which is preparing to launch a new product line...
Snap Inc (NYSE:SNAP) has announced a new multi-year agreement with Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) to power future generations of its augmented reality (AR) eyewear with Snapdragon processors. The deal centers on Snap’s subsidiary, Specs, which is preparing to launch a new product line...
(RTTNews) - German stocks climbed higher on Friday with investors reacting a bit positively to Israeli Prime Minister Benjamin Netanyahu's announcement that his country was ready for direct negotiations with Lebanon. Netanyahu, however, insisted that Israel would continue to targ
(RTTNews) - German stocks climbed higher on Friday with investors reacting a bit positively to Israeli Prime Minister Benjamin Netanyahu's announcement that his country was ready for direct negotiations with Lebanon. Netanyahu, however, insisted that Israel would continue to targ
The release of Meta's new Muse Spark model this week helped the stock recover from a selloff after a pair of legal setbacks. But the risk of a domino effect persists given the thousands of other pending cases against the company.
The release of Meta's new Muse Spark model this week helped the stock recover from a selloff after a pair of legal setbacks. But the risk of a domino effect persists given the thousands of other pending cases against the company.
Carl Lokko/iStock via Getty Images Alvotech ( ALVO ) is an Icelandic biotech company focusing on the development and manufacturing of biosimilar medicines. To scale its commercialization of its products, it partners with global pharmaceutical companies, such as Teva or Advanz Pharma, where it could then generate revenues from the shares of the sales of its products and milestone-based fees. ALVO p...
Carl Lokko/iStock via Getty Images Alvotech ( ALVO ) is an Icelandic biotech company focusing on the development and manufacturing of biosimilar medicines. To scale its commercialization of its products, it partners with global pharmaceutical companies, such as Teva or Advanz Pharma, where it could then generate revenues from the shares of the sales of its products and milestone-based fees. ALVO primarily competes with the likes of Swiss-based Sandoz or Samsung Bioepis, which also operate within the biosimilar segment. Since going public, share performance has been underwhelming and volatile. The stock is down around -63% from an all-time standpoint, while it is also down -59% over the past year alone, currently trading at merely around $4 per share range. I initiate my coverage with a buy rating. My 1-year price target of $4 presents over 12% upside from the current price of $3.6 per share. Financial Reviews Overall, fundamentals appear decent as of Q4 2025, marked by double-digit revenue growth and positive GAAP profitability. company presentation While ALVO delivered a Q4 revenue of $173 million, which is only a 13% YoY growth, the company actually clocked in a 21% YoY growth on an annual basis with $593 million FY revenue, which points to stronger commercial execution. 10K Likewise, we also see an overall improvement in profitability. For instance, GAAP net profitability turned positive, though it seems to mainly be driven by a non-cash item. The key highlight is in the adjusted EBITDA (aEBITDA), which saw a 27% YoY increase to $137 million, an important milestone in operating profitability performance. company presentation Liquidity and cash-flow situations are generally where ALVO seems to be lagging behind as of FY 2025. ALVO ended FY 2025 with $172 million of cash, a decent jump from last year’s $51 million. Yet, it mainly relied on financing cash flow from net borrowings rather than operating cash flow (OCF). Though OCF was positive $7 million in FY 2025, A...
The price of silence from western politicians and media outlets over Israel’s actions in Palestine is now being paid by Iranian and Lebanese civilians The president of the United States threatened this week to commit genocide against Iran. As Israel engages in continued bombing in Lebanon, killing more than 200 people in a single day , that fact must never be scrubbed away, not least because there...
The price of silence from western politicians and media outlets over Israel’s actions in Palestine is now being paid by Iranian and Lebanese civilians The president of the United States threatened this week to commit genocide against Iran. As Israel engages in continued bombing in Lebanon, killing more than 200 people in a single day , that fact must never be scrubbed away, not least because there is no guarantee the threat will not be revived. But as we descend towards the abyss, we need to understand where our fall began. “A whole civilisation will die tonight, never to be brought back again,” Donald Trump wrote on Tuesday. Just over a year ago, he announced : “A civilisation has been wiped out in Gaza.” The connection is not hard to trace. Trump knew Gaza had been razed by Israel, insisting it was “ not a place for people to be living ”. When he joined forces with the perpetrator of that genocide in an illegal war on Iran, the apocalyptic rubble of Gaza became a template. Owen Jones is a Guardian columnist Continue reading...